MOBIC Active Ingredient: meloxicam is used to relieve the symptoms of arthritis, primary dysmenorrhea, fever; and as an analgesic, especially where there is an inflammatory component. MOBIC is a nonsteroidal anti-inflammatory drug . Each pastel yellow tablet contains 7.5 mg or 15 mg for oral administration. Meloxicam is chemically designated as 4-hydroxy-2-methyl-N-(5methyl2thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular weight is 351.4.
Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P)app = 0.1 in n-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2.
MOBIC is available as a tablet for oral administration containing 7.5 mg or 15 mg meloxicam.
The inactive ingredients in MOBIC tablets include colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium citrate dihydrate. MOBIC Tablets have not shown equivalent systemic exposure to other approved formulations of oral meloxicam. Therefore, MOBIC Tablets are not interchangeable with other formulations of oral meloxicam product even if the total strength is the same. Do not substitute similar dose strengths of MOBIC Tablets with other formulations of oral meloxicam product.MOBIC is available as a pastel yellow, round, biconvex, uncoated tablet containing meloxicam 7.5 mg or as a pastel yellow, oblong, biconvex, uncoated tablet containing meloxicam 15 mg. The 7.5 mg tablet is impressed with the Boehringer Ingelheim logo on one side, and on the other side, the letter “M”. The 15 mg tablet is impressed with the tablet code “15” on one side and the letter “M” on the other.(meloxicam) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Meloxicam is prescribed to people who have tenderness, swelling, and pain caused by the inflammation of osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid and idiopathic arthritis (JRA/JIA). a non-steroidal anti-inflammatory drug works by blocking the enzymes responsible for making prostaglandins,compounds that contribute to inflammation, especially joint inflammation.
By reducing the levels of prostaglandins, inflammation and other symptoms can be reduced.
A double-blind, controlled study was conducted in the U.S. to evaluate the safety and efficacy of Mobic. The 12-week study involved 464 patients who had osteoarthritis of the knee and hip. When three different doses of Mobic (3.5 mg, 7.5 mg, and 15 mg daily) were compared to placebo, results indicated that both the 7.5 and 15 mg daily doses of Mobic significantly decreased symptoms of pain, function, and stiffness in patients, with a low incidence of gastrointestinal side effect.